Health
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitatingData will be submitted to regulatory authorities Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrat
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MSaNoVyiQkMLafN4Lv5PPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitating","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Data will be submitted to regulatory authorities","length":48,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":371,"olType":false},{"type":"text","content":"Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint. The primary endpoint was measured by the time from randomisation to the first MOGAD relapse during the double-blind treatment period (p=0.0025). The results were shared today at a late-breaking oral presentation in the Clinical Trials Plenary Session at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago.","length":682,"tagName":"p"},{"type":"text","content":"“MOGAD is a rare autoimmune disease that can attack the optic nerves, brain and spinal cord and cause severe and unpredictable relapses, resulting in accumulating neurological damage, vision loss and disability. Currently, there are no approved treatment options for this debilitating disease” said Michael Levy, MD, PhD, Associate Professor at Harvard School and Massachusetts General Hospital. “ENSPRYNG is the first medicine to show a meani...